Differential expression of TRAIL and its receptors in benign and malignant prostate tissues

Sanlioglu A. D., Koksal I. T., Ciftcioglu A., Baykara M., Lüleci G., Sanlioglu S.

JOURNAL OF UROLOGY, cilt.177, sa.1, ss.359-364, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 177 Sayı: 1
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.juro.2006.08.087
  • Dergi Adı: JOURNAL OF UROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.359-364
  • Anahtar Kelimeler: prostate, prostatic neoplasms, TNF-related apoptosis-inducing ligand, apoptosis, gene therapy, CANCER IN-VITRO, INDUCED APOPTOSIS, GENE-THERAPY, CELLS, MECHANISMS, CARCINOMA, VIVO
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Purpose: Because TRAIL (tumor necrosis factor related apoptosis inducing ligand) selectively kills cancer cells without damaging normal cells, a gene therapy approach using TRAIL is feasible for treating patients with cancer. However, recent publications suggest that significant portions of human tumors appear to be TRAIL resistant. Furthermore, there is some controversy about whether TRAIL receptor composition influences TRAIL sensitivity in cancer cells. Our recent studies suggest. that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate, breast and lung cancer cells. We investigated TRAIL and TRAIL receptor expression profiles during prostate carcinogenesis to evaluate their potential as biomarkers and predict the feasibility of a related gene therapy approach.